Drug Trial Radar · NCT07797153
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
368
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN033 versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/L1 inhibitor therapy.
Conditions
- Recurrent or Metastatic Cervical Cancer
Interventions
JSKN033Drug
JSKN033 should be administered subcutaneously
DocetaxelDrug
Docetaxel
TopotecanDrug
Topotecan
Gemcitabine (GEM)Drug
Gemcitabine
PemetrexedDrug
Pemetrexed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC) as per RECIST 1.1Time frame: Up to approximately 27 months
- Overall Survival (OS)Time frame: Up to approximately 27 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Fudan University
Shanghai, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.